FDA Approvals, News & UpdatesFollicular LymphomaLymphomaNewsworthy

Revlimid Now Approved for Follicular Lymphoma and Marginal-Zone Lymphoma

August 2019 Vol 5 No 4

In May 2019, the FDA approved the new combination of Revlimid (lenalidomide; from Celgene) plus Rituxan (rituximab; from Genentech) for the treatment of patients with follicular lymphoma or marginal-zone lymphoma. Both drugs were previously approved for different cancer types.

This new approval was based on the results of 2 clinical trials in patients with relapsed or refractory follicular lymphoma or with marginal-zone lymphoma who received Revlimid plus Rituxan or placebo plus Rituxan.

The average time without disease progression was 39.4 months with Revlimid plus Rituxan versus 14.1 months with placebo plus Rituxan. Overall, 80% of the patients with follicular lymphoma responded to Revlimid plus Rituxan therapy versus 55.4% of patients who responded to placebo plus Rituxan; these rates were 65% versus 44%, respectively, in ­patients with marginal-zone lymphoma.

Recommended For You
Breast CancerFDA Approvals, News & Updates
Trodelvy New Therapy Approved for Triple-Negative Breast Cancer
In April, 2020, the FDA approved Trodelvy for the treatment of adults with metastatic triple-negative breast cancer after 2 or more previous therapies.
BiomarkersFDA Approvals, News & Updates
Tabrecta Approved for NSCLC with MET Biomarker

On May 6, 2020, the FDA approved Tabrecta (capmatinib; from Novartis), an oral kinase inhibitor, for adults with metastatic (spreading) non–small-cell lung cancer (NSCLC).

FDA Approvals, News & UpdatesOvarian Cancer
Zejula Now Approved as First-Line Maintenance Therapy in All Patients with Ovarian Cancer

On April 29, 2020, the FDA approved Zejula (niraparib; from GlaxoSmithKline), an oral PARP inhibitor, as the first PARP inhibitor approved for first-line maintenance (long-term) therapy for all patients with advanced ovarian cancer (including epithelial ovarian, fallopian tube, or primary peritoneal cancer) whose cancer had a complete or partial response to platinum-based chemotherapy.

CholangiocarcinomaFDA Approvals, News & Updates
Pemazyre First Therapy Approved for Cholangiocarcinoma with FGFR2 Biomarker
In April, the FDA approved Pemazyre, the first targeted drug for patients with advanced cholangiocarcinoma and a biomarker called FGFR2 gene fusion.
Last modified: August 28, 2019

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.